Enanta Pharma Q2 loss narrows on higher AbbVie royalties, lower costs

Enanta Pharmaceuticals

11/05/2026 21:11

Overview

Biotech drug developer's fiscal Q2 revenue rose, slightly beating analyst expectations

Net loss for fiscal Q2 narrowed compared to prior-year quarter

Company ended Q2 with $227 mln in cash and marketable securities

Outlook

Company expects cash and marketable securities to fund operations into fiscal 2029

Enanta plans to report topline data from EDP-978 Phase 1 trial in 4Q 2026

Company expects to file IND for EPS-3903 and select MRGPRX2 candidate in 2H 2026

Result Drivers

ROYALTY REVENUE - Revenue growth attributed to higher royalties from AbbVie's MAVYRET/MAVIRET hepatitis C treatment

LOWER R&D EXPENSES - Research and development expenses declined due to reduced clinical trial costs for RSV programs, partially offset by higher immunology program spending

REDUCED ADMINISTRATIVE COSTS - General and administrative expenses fell, primarily due to lower stock-based compensation

Company press release: ID:nBwQ5Tqta

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Slight Beat*
$17.16 mln
$17.09 mln (5 Analysts)
Q2 EPS
-$0.45
Q2 Net Income
-$13.09 mln
Q2 Operating Expenses
$29.01 mln
Q2 Operating Income
-$11.85 mln
Q2 Pretax Profit
-$13.08 mln


*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Enanta Pharmaceuticals Inc is $20.00, about 30.4% above its May 8 closing price of $15.34

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)